共 50 条
Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study
被引:8
|作者:
Bae, Charles J.
[1
]
Zee, Phyllis C.
[2
]
Leary, Eileen B.
[3
]
Fuller, Douglas S.
[4
]
Macfadden, Wayne
[4
,6
]
Candler, Shawn
[4
]
Steininger, Teresa L.
[3
]
Husain, Aatif M.
[5
]
机构:
[1] Univ Penn, Penn Med, Philadelphia, PA USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[3] Jazz Pharmaceut, Palo Alto, CA USA
[4] Jazz Pharmaceut, Philadelphia, PA USA
[5] Duke Univ, Med Ctr, Durham, NC USA
[6] 2005 Market St, Philadelphia, PA 19103 USA
来源:
关键词:
Narcolepsy;
Excessive daytime sleepiness;
Epworth Sleepiness Scale;
Cataplexy;
Sodium oxybate;
Low -sodium oxybate;
BLOOD-PRESSURE;
WITHDRAWAL;
BURDEN;
D O I:
10.1016/j.sleep.2023.05.023
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Objectives: The Transition Experience of persons with Narcolepsy taking Oxybate in the Real-world (TENOR) study was conducted to provide real-world insight into the experience of people with narcolepsy switching from sodium oxybate (SXB) to low-sodium oxybate (LXB; 92% less sodium than SXB). Methods: TENOR is a patient-centric, prospective, observational, virtual-format study. Participants were adults with narcolepsy (type 1 or 2) who were transitioning from SXB to LXB treatment (& PLUSMN;7 days from LXB initiation). Effectiveness and tolerability data were collected online from baseline (taking SXB) through 21 weeks (taking LXB) via daily and weekly diaries and questionnaires, including the Epworth Sleepiness Scale (ESS), the Functional Outcomes of Sleep Questionnaire, short version (FOSQ-10), and the British Columbia Cognitive Complaints Inventory (BC-CCI). Results: TENOR participants (N = 85) were 73% female with a mean (SD) age of 40.3 (13.0) years. Mean (SD) ESS scores decreased numerically throughout the transition from SXB to LXB (baseline: 9.9 [5.2]; week 21: 7.5 [4.7]), with 59.5% and 75.0% of participants having scores in the normal range (& LE;10) at baseline and week 21, respectively. Mean (SD) FOSQ-10 scores (baseline: 14.4 [3.4]; week 21: 15.2 [3.2]) and BC-CCI scores (baseline: 6.1 [4.4]; week 21: 5.0 [4.3]) also remained stable. The most common symptoms related to tolerability reported by participants at baseline were sleep inertia, hyperhidrosis, and dizziness (45.2%, 40.5%, and 27.4%, respectively), which decreased in prevalence by week 21 (33.8%, 13.2%, and 8.8%, respectively). Conclusions: Findings from TENOR confirm maintenance of effectiveness and tolerability when transitioning from SXB to LXB treatment. & COPY; 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:65 / 74
页数:10
相关论文